In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew Launches Gender-Specific Knees

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew is entering the increasingly crowded U.S. gender-specific knee replacement market

You may also be interested in...



Zimmer Cites Lack Of Hip Resurfacing System As Drag On Growth

Zimmer's sales of total artificial hips are being constrained by competition from less invasive hip resurfacing procedures, while knee sales are being pinched by slower-than-expected adoption of the Gender Solutions knee, the firm says

Zimmer Cites Lack Of Hip Resurfacing System As Drag On Growth

Zimmer's sales of total artificial hips are being constrained by competition from less invasive hip resurfacing procedures, while knee sales are being pinched by slower-than-expected adoption of the Gender Solutions knee, the firm says

Knees for the ladies

Zimmer announces 510(k) clearance of its Gender Solutions high-flex knee replacement May 10. The knee, based upon the firm's NexGen technology, is tailored to fit women and small men by incorporating a narrower shape and unique angle by which the kneecap tracks over the femur. Zimmer estimates that two-thirds of knee replacements in the $4.6 bil. market are for women. The firm plans to spend $10 mil. a year in direct-to-consumer advertising for the product (1"The Gray Sheet" March 27, 2006, p. 10)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel